Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis

BackgroundIdentifying Plasmodium vivax antigen-specific antibodies associated with P. vivax infection and protective immunity is key to the development of serosurveillance tools and vaccines for malaria. Antibody targets of P. vivax can be identified by seroepidemiological studies of individuals living in P. vivax-endemic areas, and is an important strategy given the limited ability to culture P. vivax in vitro. There have been numerous studies investigating the association between P. vivax antibody responses and P. vivax infection, but there has been no standardization of results to enable comparisons across populations.MethodsWe performed a systematic review with meta-analysis of population-based, cross-sectional, case-control, and cohort studies of individuals living in P. vivax-endemic areas. We searched 6 databases and identified 18 studies that met predefined inclusion and quality criteria, and examined the association between antibody responses to P. vivax antigens and P. vivax malaria.ResultsThe majority of studies were published in South America (all from Brazil) and the rest from geographically diverse areas in the Asia-Pacific region. Considerable heterogeneity in estimates was observed, but IgG responses to PvCSP, PvMSP-119, PvMSP-9RIRII, and PvAMA1 were associated with increased odds of P. vivax infection in geographically diverse populations. Potential sources of heterogeneity included study design, different transmission intensities and transmigrant populations. Protective associations were observed for antibodies to PvMSP-119, PvMSP-1NT, PvMSP-3α and PvMSP-9NT antigens, but only in single geographical locations.ConclusionsThis systematic review revealed several antigen-specific antibodies that were associated with active infection and protective immunity, which may be useful biomarkers. However, more studies are needed on additional antigens, particularly cohort studies to increase the body of evidence for protective immunity. More studies representing diverse geographical regions encompassing varying P. vivax endemicities are needed to validate the generalizability of the findings and to provide a solid evidence base for the use of P. vivax antigens in vaccines and serosurveillance tools.

[1]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[2]  A. Holder,et al.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. , 1991, Molecular and biochemical parasitology.

[3]  E. Vargas-Serrato,et al.  Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum. , 2002, Molecular and biochemical parasitology.

[4]  M. Chen-Mok,et al.  Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. , 2011, The American journal of tropical medicine and hygiene.

[5]  R. Price,et al.  Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. , 2012, Advances in parasitology.

[6]  Caroline W. Kabaria,et al.  The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009 , 2010, PLoS neglected tropical diseases.

[7]  K. Marsh,et al.  Immune effector mechanisms in malaria , 2006, Parasite immunology.

[8]  C. G. Black,et al.  The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoite. , 2002, Molecular and biochemical parasitology.

[9]  A. Holder,et al.  A malaria merozoite surface protein (MSP1)-structure, processing and function. , 1992, Memorias do Instituto Oswaldo Cruz.

[10]  R. Price,et al.  Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. , 2008, The Journal of infectious diseases.

[11]  Pedro Alonso,et al.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. , 2011, The New England journal of medicine.

[12]  Hyun Park,et al.  Development and evaluation of an immunochromatographic kit for the detection of antibody to Plasmodium vivax infection in South Korea. , 2003, Yonsei medical journal.

[13]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[14]  M. Galinski,et al.  Influence of HLA-DRB1 and HLA-DQB1 Alleles on IgG Antibody Response to the P. vivax MSP-1, MSP-3α and MSP-9 in Individuals from Brazilian Endemic Area , 2012, PloS one.

[15]  M. Galinski,et al.  Plasmodium vivax reticulocyte binding protein-2 (PvRBP-2) shares structural features with PvRBP-1 and the Plasmodium yoelii 235 kDa rhoptry protein family. , 2000, Molecular and biochemical parasitology.

[16]  J. Sattabongkot,et al.  Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. , 1989, Science.

[17]  M. Galinski,et al.  B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon. , 2011, Vaccine.

[18]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[19]  T. Out,et al.  Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. , 1994, Immunology.

[20]  Jack S. Richards,et al.  The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.

[21]  C. Lim,et al.  Prevalence of antibodies to the circumsporozite protein of Plasmodium vivax in five different regions of Korea , 2003, Tropical medicine & international health : TM & IH.

[22]  J. McCarthy,et al.  Using serological measures to monitor changes in malaria transmission in Vanuatu , 2010, Malaria Journal.

[23]  M. Galinski,et al.  Naturally Acquired Immune Responses to P. vivax Merozoite Surface Protein 3α and Merozoite Surface Protein 9 Are Associated with Reduced Risk of P. vivax Malaria in Young Papua New Guinean Children , 2013, PLoS neglected tropical diseases.

[24]  M. Galinski,et al.  Plasmodium vivax: Merozoites, invasion of reticulocytes and considerations for malaria vaccine development. , 1996, Parasitology today.

[25]  B. M. Sanchez,et al.  Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well‐consolidated settlement of the Amazon Region , 2012, Tropical medicine & international health : TM & IH.

[26]  N. White.  Determinants of relapse periodicity in Plasmodium vivax malaria , 2011, Malaria Journal.

[27]  H. D. del Portillo,et al.  A Reduced Risk of Infection with Plasmodium vivax and Clinical Protection against Malaria Are Associated with Antibodies against the N Terminus but Not the C Terminus of Merozoite Surface Protein 1 , 2006, Infection and Immunity.

[28]  J. Richards,et al.  The future for blood‐stage vaccines against malaria , 2009, Immunology and cell biology.

[29]  M. Galinski,et al.  Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. , 2008, Vaccine.

[30]  Kap-No Lee,et al.  Evaluation of rapid immunocapture assays for diagnosis of Plasmodium vivax in Korea , 2001, Parasitology Research.

[31]  Tong‐Soo Kim,et al.  ELISA detection of vivax malaria with recombinant multiple stage-specific antigens and its application to survey of residents in endemic areas. , 2003, The Korean journal of parasitology.

[32]  S. Hoffman,et al.  Humoral immune responses against Plasmodium vivax MSP1 in humans living in a malaria endemic area in Flores, Indonesia. , 1998, The Southeast Asian journal of tropical medicine and public health.

[33]  J. Simpson,et al.  New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women , 2012, The Journal of infectious diseases.

[34]  C. Coban,et al.  Serologic Markers in Relation to Parasite Exposure History Help to Estimate Transmission Dynamics of Plasmodium vivax , 2011, PloS one.

[35]  A. Saul,et al.  Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1. , 1995, Molecular and biochemical parasitology.

[36]  C. Chitnis,et al.  Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection , 2008, Proceedings of the National Academy of Sciences.

[37]  A. Holder,et al.  A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion- inhibiting antibodies , 1990, The Journal of experimental medicine.

[38]  Young Ree Kim,et al.  Comparison of Immunological Responses to the Various Types of Circumsporozoite Proteins of Plasmodium vivax in Malaria Patients of Korea , 2004, Microbiology and immunology.

[39]  M. Galinski,et al.  Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites. , 1999, Experimental parasitology.

[40]  H. Webster,et al.  Naturally acquired circumsporozoite antibodies and their role in protection in endemic falciparum and vivax malaria. , 1991, The American journal of tropical medicine and hygiene.

[41]  H. Kishino,et al.  Recent independent evolution of msp1 polymorphism in Plasmodium vivax and related simian malaria parasites. , 2007, Molecular and biochemical parasitology (Print).

[42]  J. Sattabongkot,et al.  Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. , 2005, Vaccine.

[43]  M. Fay,et al.  Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 , 2008, PloS one.

[44]  M. Patarroyo,et al.  High polymorphism in Plasmodium vivax merozoite surface protein-5 (MSP5) , 2006, Parasitology.

[45]  C. Chitnis,et al.  Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Arruda,et al.  HLA class II and antibody responses to circumsporozoite protein repeats of P. vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malaria. , 2004, Acta tropica.

[47]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[48]  David Schellenberg,et al.  A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.

[49]  B. Crabb,et al.  Towards a Vaccine against Plasmodium vivax Malaria , 2007, PLoS medicine.

[50]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[51]  C. Coban,et al.  Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa, Turkey. , 2008, The American journal of tropical medicine and hygiene.

[52]  I. Mueller,et al.  Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous Plasmodium vivax Strains in Papua New Guinean Children , 2009, Infection and Immunity.

[53]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[54]  H. D. del Portillo,et al.  Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay , 2010, Malaria Journal.

[55]  U. d’Alessandro,et al.  Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia , 2012, Malaria Journal.

[56]  Mary R. Galinski,et al.  A reticulocyte-binding protein complex of plasmodium vivax merozoites , 1992, Cell.

[57]  B. Genton,et al.  A review of malaria vaccine clinical projects based on the WHO rainbow table , 2012, Malaria Journal.

[58]  J. Adams,et al.  Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein , 1997, Infection and immunity.

[59]  Douglas G. Altman,et al.  Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .

[60]  J. Rayner,et al.  Extensive polymorphism in the Plasmodium vivax merozoite surface coat protein MSP-3α is limited to specific domains , 2002, Parasitology.

[61]  H. D. del Portillo,et al.  High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms , 2013, Malaria Journal.

[62]  R. Snow,et al.  Serologic Markers for Detecting Malaria in Areas of Low Endemicity, Somalia, 2008 , 2010, Emerging infectious diseases.

[63]  M. Galinski,et al.  Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domain. , 1999, Molecular and biochemical parasitology.

[64]  John P A Ioannidis,et al.  Interpretation of tests of heterogeneity and bias in meta-analysis. , 2008, Journal of evaluation in clinical practice.

[65]  C. Chitnis,et al.  The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes , 1996, The Journal of experimental medicine.

[66]  M. Alpers,et al.  Identification of Plasmodium vivax-like human malaria parasite , 1993, The Lancet.

[67]  T. Horii,et al.  Plasmodium vivax serine repeat antigen (SERA) multigene family exhibits similar expression patterns in independent infections. , 2006, Molecular and biochemical parasitology.

[68]  Prashant Yadav,et al.  A Research Agenda for Malaria Eradication: Vaccines , 2019 .

[69]  M. Galinski,et al.  Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. , 2013, Advances in parasitology.

[70]  V. Nussenzweig,et al.  Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax , 1982, The Journal of experimental medicine.

[71]  Kwaku Poku Asante,et al.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. , 2012, The New England journal of medicine.

[72]  B. M. Sanchez,et al.  Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon. , 2010, The American journal of tropical medicine and hygiene.

[73]  M. Galinski,et al.  Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. , 2005, The American journal of tropical medicine and hygiene.